Summary
Selexis is looking for validated targets, gene expression tools and preclinical stage protein therapeuticsOrganization name
Selexis SAProfile
Headquartered in Geneva, Switzerland, Selexis is a leading biotechnology company dedicated to the development of innovative technologies and expert services for mammalian cell line development.
Selexis offers comprehensive and rapid solutions for stable, high yield mammalian cell lines used in recombinant protein manufacturing of therapeutic drugs. The Company's unique SURE Cell Line DevelopmentSM services and technology, which includes Selexis Genetic ElementsTM, reduce traditional cell line development (e.g. DHFR) from 12 months to ~5 weeks with an increase in expression more than 20 fold without any change in the scale-up process.
Selexis Genetic ElementsTM improve the speed, yield and stability of production cell lines. Selexis Genetic ElementsTM allow stable cell line development in ~5 weeks (after transfection to isolated cell clone). Additionally, Selexis Genetic ElementsTM have been found to increase recombinant protein expression in mammalian cells in suspension and in serum-free more than 20 fold.
Selexis continues to seek strategic alliances and licensing opportunities. They are especially interested in:
- Protein therapeutics (antibody and non-antibody alike; preferably with some animal data)
- Vaildated targets
- Technology/tools that augment or enhance gene expression
For contact please visit Selexis website or use the feedback link below for direct access.
print this page
